Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

Phase III trial results announced for Riquent

Feb. 20, 2003

New COX-2 inhibitors covered by Pfizer patents

Feb. 14, 2003

BMS and Pharmacopeia jointly report new p38 kinase inhibitors

Feb. 14, 2003

Use of rhBMP-2 in lumbar arthrodesis

Feb. 12, 2003

Raptiva enters phase II trial in psoriatic arthritis

Feb. 11, 2003

New inhibitors of iNOS with oral antiinflammatory activity identified at AstraZeneca

Feb. 10, 2003

No significant effects reported for celecoxib on fracture healing in rats

Feb. 10, 2003

GlycoDesign regains rights to Core 2 inhibitors

Feb. 6, 2003

Pfizer presents new CCR1 antagonists for arthritis and other disorders

Feb. 5, 2003

Clinical use of a humanized anti-IL-6R monoclonal antibody in rheumatoid arthritis

Feb. 4, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...